000756 新华制药
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,474,697-6.25%8,100,8457,502,9876,560,0786,005,587
减:营业总成本2,328,929-5.33%7,530,9057,020,4786,173,7365,585,070
    其中:营业成本1,795,730-0.86%5,709,1425,465,6564,786,4104,190,990
               财务费用2,955-81.02%16,35132,01952,90383,710
               资产减值损失----(69,283)(43,526)(33,267)(45,159)
公允价值变动收益------------
投资收益1,1891,423.42%9,5838,3658,0175,611
    其中:对联营企业和合营企业的投资收益1,1891,423.42%1,418447(1,089)(2,978)
营业利润170,557-8.20%534,582476,707425,591422,485
利润总额168,772-8.73%532,686471,774421,233411,638
减:所得税费用23,507-23.95%26,57945,66559,15964,525
净利润145,264-5.68%506,107426,110362,074347,113
减:非控股权益3,38540.64%9,59515,04713,52622,254
股东净利润141,879-6.41%496,512411,063348,548324,860

市场价值指针
每股收益 (元) *0.210-8.70%0.7400.6200.5600.520
每股派息 (元) *----0.2500.2000.1500.150
每股净资产 (元) *6.9838.82%6.7496.1625.5285.184
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容